Overview

Toripalimab Combined With Chemoradiotherapy in Patients With Locoregionally-advanced Nasopharyngeal Carcinoma

Status:
Not yet recruiting

Trial end date:
2024-12-15

Target enrollment:

Participant gender:

Summary

This is an open-label, parallel controlled, phase IIa exploratory study that evaluates the efficacy and safety of Toripalimab (PD-1 Antibody) combined with induction chemotherapy （Albumin-bound paclitaxel and cisplatin ）and concurrent chemoradiotherapy in the treatment of nasopharyngeal carcinoma and explores the biomarkers that can predict the efficacy and toxicity of the treatment.

Phase:

Phase 2

Details

Lead Sponsor:

First People's Hospital of Foshan

Treatments:

Albumin-Bound Paclitaxel
Paclitaxel